QIAGEN Acquires 96% Stake in BLIRT S.A.
May 11, 2022
QIAGEN N.V. has acquired a more than 96% majority ownership stake in BLIRT S.A., a Gdansk, Poland–based manufacturer of recombinant enzymes and molecular biology reagents. The deal (expected to close in Q2 2022) adds R&D and industrial-scale manufacturing capacity, expands QIAGEN's sample technologies business and broadens its geographic and commercial reach while strengthening supply-chain resilience.
- Buyers
- QIAGEN N.V.
- Targets
- BLIRT S.A.
- Sellers
- A group of leading shareholders of BLIRT S.A.
- Industry
- Biotechnology
- Location
- Pomeranian Voivodeship, Poland
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Repligen Completes Acquisition of BioLife Solutions
July 23, 2026
Medical Devices
Repligen agreed to acquire BioLife Solutions in a cash-and-stock transaction valued at approximately $1.5 billion, and later announced that the acquisition was completed. The deal expands Repligen’s cell and gene therapy offering with BioLife’s biopreservation media and cell-processing products, while broadening BioLife’s access to Repligen’s global commercial reach.
-
QIAGEN Acquires Genoox
May 12, 2025
Biotechnology
QIAGEN has signed a definitive agreement to acquire Genoox, the developer of the AI-powered Franklin clinical genomics platform, for $70 million in cash plus up to $10 million in milestone payments. The acquisition adds Genoox's cloud-based AI interpretation capabilities to QIAGEN Digital Insights, expanding QIAGEN's clinical genomics and diagnostic software offerings for labs and healthcare organizations worldwide.
-
Gilead Sciences Acquires MiroBio
September 20, 2022
Biotechnology
Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.
-
Ginkgo Bioworks to Acquire Zymergen
July 25, 2022
Biotechnology
Ginkgo Bioworks (NYSE: DNA) has entered into a definitive agreement to acquire Zymergen (Nasdaq: ZY) in an all-stock transaction valued at approximately $300 million market capitalization. The deal is expected to close in the first quarter of 2023, pending Zymergen stockholder approval, regulatory approvals, and other customary closing conditions.
-
CellCarta Acquires Biogazelle
December 14, 2021
Biotechnology
CellCarta has acquired Biogazelle, a Ghent-based leader in digital PCR (dPCR), qPCR and RNASeq assay development, to strengthen and expand its genomic capabilities. The acquisition creates a Center of Excellence for complex genomic biomarker assay development within CellCarta and broadens its service offering for pharmaceutical and biotech clients across discovery and clinical stages.
-
PerkinElmer Acquires BioLegend for Approximately $5.25 Billion
July 26, 2021
Biotechnology
PerkinElmer, Inc. agreed to acquire BioLegend, a leading developer of antibodies and life-science reagents, for approximately $5.25 billion in cash and stock. The acquisition expands PerkinElmer's life-science franchise into high-growth areas such as biologics, cell and gene therapy, and proteogenomics, and is expected to be accretive to earnings.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.